How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Description:
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.
Sponsor:
NovartisContacts:
Novartis Pharmaceuticalsnovartis.email@novartis.com
+41613241111
Government Study Link:
NCT06780670 - Click here to see study onClinicalTrials.gov
AAA817
Isotope(s):
Target(s):
- PSMA
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
Singapore 🇸🇬
Novartis Investigative Site
Singapore
